Medicare Enrolled
Dr. Stavroula Otis, M.D.
Hematology & Oncology · Orange, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Otis from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Otis?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Otis
Dr. Stavroula Otis is a hematology & oncology specialist in Orange, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Otis performed 121,898 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Otis received a total of $23,262 from 70 pharmaceutical and/or device companies across 990 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Otis is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 5% volume in CA
$23,262 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗121,898
Medicare services
Top 5% in CA for hematology & oncology
Not available
Unique patients (not deduplicated)
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
72,750 | $1 | $3 |
| Denosumab injection (Prolia/Xgeva) | 25,560 | $18 | $61 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
6,081 | $6 | $21 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
5,421 | $6 | $21 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
3,518 | $0 | $0 |
| Injection, granisetron hydrochloride, 100 mcg | 1,456 | $0 | $1 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,447 | $104 | $361 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,376 | $8 | $21 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,366 | $8 | $20 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
747 | $13 | $41 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
328 | $123 | $402 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
261 | $26 | $86 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
211 | $1 | $3 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
206 | $26 | $83 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
197 | $31 | $100 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 149 | $132 | $546 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
139 | $61 | $196 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
114 | $60 | $194 |
| New patient office visit, complex (60-74 min) | 114 | $178 | $625 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
94 | $68 | $210 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
85 | $152 | $501 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
78 | $75 | $263 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
54 | $14 | $44 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
54 | $1 | $5 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
34 | $87 | $302 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
21 | $108 | $347 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
19 | $34 | $56 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
18 | $72 | $181 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
60.4% high complexity
35.7% medium
3.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$23,262
Total received (2018-2024)
Avg $3,323/year across 7 years
Top 19% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
70
Companies
990
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,529
2023
$2,912
2022
$5,514
2021
$1,337
2020
$1,921
2019
$4,377
2018
$4,673
Payments by company (2024)
Daiichi Sankyo Inc.
$272
Novartis Pharmaceuticals Corporation
$258
Gilead Sciences, Inc.
$215
Janssen Biotech, Inc.
$201
Celgene Corporation
$194
BeiGene USA, Inc.
$127
Takeda Pharmaceuticals U.S.A., Inc.
$100
Merck Sharp & Dohme LLC
$97
E.R. Squibb & Sons, L.L.C.
$88
PFIZER INC.
$85
Incyte Corporation
$77
ABBVIE INC.
$58
ARRAY BIOPHARMA INC
$52
Rigel Pharmaceuticals, Inc.
$43
Genentech USA, Inc.
$42
AstraZeneca Pharmaceuticals LP
$41
Tolmar, Inc.
$41
PUMA BIOTECHNOLOGY, INC.
$39
Boehringer Ingelheim Pharmaceuticals, Inc.
$38
Exelixis Inc.
$37
Regeneron Healthcare Solutions, Inc.
$37
EMD Serono, Inc.
$34
Lilly USA, LLC
$34
GENZYME CORPORATION
$28
Coherus Biosciences Inc.
$27
Ipsen Biopharmaceuticals, Inc
$27
SpringWorks Therapeutics, Inc.
$26
Karyopharm Therapeutics Inc.
$26
Amneal Pharmaceuticals LLC
$25
Fennec Pharmaceuticals, Inc.
$25
MorphoSys, US Inc.
$25
Stemline Therapeutics Inc.
$22
Janssen Pharmaceuticals, Inc
$22
Astellas Pharma US Inc
$18
Bayer Healthcare Pharmaceuticals Inc.
$17
GlaxoSmithKline, LLC.
$16
Kyowa Kirin, Inc.
$15
Top 3 companies account for 29.5% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$4,773
E.R. Squibb & Sons, L.L.C.
$2,011
AstraZeneca Pharmaceuticals LP
$1,786
Merck Sharp & Dohme Corporation
$1,228
PFIZER INC.
$1,143
NOVARTIS PHARMACEUTICALS CORPORATION
$1,050
Janssen Biotech, Inc.
$922
Gilead Sciences, Inc.
$823
Amgen Inc.
$684
Celgene Corporation
$638
Pharmacyclics LLC, An AbbVie Company
$602
Genentech USA, Inc.
$599
EMD Serono, Inc.
$521
Lilly USA, LLC
$431
AbbVie, Inc.
$413
Incyte Corporation
$410
BeiGene USA, Inc.
$385
Puma Biotechnology, Inc.
$366
Daiichi Sankyo Inc.
$330
Astellas Pharma US Inc
$316
Bayer HealthCare Pharmaceuticals Inc.
$282
ARRAY BIOPHARMA INC
$274
Boehringer Ingelheim Pharmaceuticals, Inc.
$272
Merck Sharp & Dohme LLC
$207
ABBVIE INC.
$185
Exelixis Inc.
$158
AbbVie Inc.
$156
GENZYME CORPORATION
$136
Teva Pharmaceuticals USA, Inc.
$121
Array BioPharma Inc.
$115
MEDIVATION FIELD SOLUTIONS LLC
$112
Takeda Pharmaceuticals U.S.A., Inc.
$100
Dendreon Pharmaceuticals LLC
$93
Seagen Inc.
$90
Foundation Medicine, Inc.
$86
Janssen Products, LP
$85
Kite Pharma, Inc.
$79
PUMA BIOTECHNOLOGY, INC.
$77
Karyopharm Therapeutics Inc.
$76
GlaxoSmithKline, LLC.
$76
Verastem, Inc.
$73
TOLMAR Pharmaceuticals, Inc.
$73
Coherus Biosciences Inc.
$70
Partner Therapeutics, Inc.
$66
Alexion Pharmaceuticals, Inc.
$58
MorphoSys, US Inc.
$50
Bayer Healthcare Pharmaceuticals Inc.
$45
Rigel Pharmaceuticals, Inc.
$43
Epizyme, Inc.,
$41
Tolmar, Inc.
$41
Regeneron Healthcare Solutions, Inc.
$37
Aveo Pharmaceuticals, Inc.
$34
Clovis Oncology, Inc.
$34
Kyowa Kirin, Inc.
$32
Eisai Inc.
$27
Ipsen Biopharmaceuticals, Inc
$27
SpringWorks Therapeutics, Inc.
$26
Amneal Pharmaceuticals LLC
$25
Fennec Pharmaceuticals, Inc.
$25
Aurobindo Pharma USA, Inc.
$25
SERVIER PHARMACEUTICALS LLC
$24
Mylan Institutional Inc.
$24
Janssen Pharmaceuticals, Inc
$23
Stemline Therapeutics Inc.
$22
Agios Pharmaceuticals, Inc.
$21
TESARO, Inc.
$20
Adaptive Biotechnologies Corporation
$20
Organon LLC
$18
EISAI INC.
$18
Cumberland Pharmaceuticals, Inc.
$14
Top 3 companies account for 36.8% of all-time payments
Associated products mentioned in payments ›
AFINITOR · ALIMTA · AVASTIN · Abraxane · Aliqopa · Avastin · BALVERSA · BAVENCIO · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Braftovi · CABOMETYX · CALQUENCE · CYRAMZA · Cabometyx · Copiktra · DARZALEX · ELAHERE · ELIGARD · ELIQUIS · ELITEK · ELZONRIS · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · Enhertu · Erleada · FARESTON · FASLODEX · FOTIVDA · FOUNDATIONONE · FOUNDATIONONE CDX · FRUZAQLA · Fabhalta · Folotyn · Fulphila · GAZYVA · GILOTRIF · Halaven · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · Itovebi · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kadcyla · Kaletra · Kyprolis · LEUKINE · LIBTAYO · LORBRENA · LUMAKRAS · LUPRON DEPOT · LYNPARZA · Lenvima · Leukine · Lupron · Lupron Depot · MEKINIST · MONJUVI · MVASI · NERLYNX · NEXPLANON · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OGSIVEO · ONUREG · OPDIVO · OPDUALAG · Onivyde · PADCEV · PLUVICTO · PROMACTA · PROVENGE · Padcev · Pedmark · Perjeta · Phesgo · Polivy · Pomalyst · Poteligeo · Prolia · REBLOZYL · RUXIENCE · RYBREVANT · RYDAPT · Rezlidhia · Rubraca · SANCUSO · SARCLISA · SOLIRIS · SUTENT · Stivarga · TAFINLAR · TAGRISSO · TALVEY · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VOTRIENT · Vectibix · Venclexta · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xofigo · Xtandi · Yescarta · ZEJULA · ZYTIGA · clonoSEQ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
243
County median income
$113,702
Nearest hospital to ZIP centroid (approximate)
PROVIDENCE ST. JOSEPH HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Otis is a mixed practice specialist, with above-average Medicare volume (top 5% in CA), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Otis experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Otis performed 72,750 iron infusion (injectafer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Otis receive payments from pharmaceutical companies?
Yes. Dr. Otis received a total of $23,262 from 70 companies across 990 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Otis's costs compare to other hematology & oncology specialists in Orange?
Dr. Otis's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Otis) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Orange
Browse hematology & oncology specialists in Orange ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology